Novo Nordisk Heart Drug Fails Key Study

Novo Nordisk, a major drug company, saw its shares fall after a new heart drug failed. The drug, called ziltivekimab, was in a late-stage study. It aimed to help patients with heart disease and kidney problems.

The study found the drug did not significantly lower serious heart problems. This news is a setback for Novo Nordisk. The company hoped ziltivekimab would expand its reach beyond diabetes and weight loss drugs.

Novo Nordisk still has other drugs in its pipeline. But this trial result means one promising treatment will not move forward. This affects the company's plans for new medicines for heart health.

Investors watch these trials closely. A successful trial can boost a company's stock. A failure often causes stock prices to drop, as seen with Novo Nordisk today.

Source: CNBC